Neural Therapeutics Inc.
NURL
CNSX
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -664.05% | 37.64% | 36.57% | -11.05% | 58.24% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8,667.27% | -158.24% | -60.00% | 105.77% | -9.84% |
| Change in Net Operating Assets | -69.64% | -36.13% | 175.85% | -16.45% | -70.09% |
| Cash from Operations | -461.63% | -188.14% | 99.63% | 79.40% | 17.90% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -36.05% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -100.00% | 100.00% |
| Cash from Financing | -- | 560.85% | -- | -25.85% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -449.42% | 594.89% | 99.18% | 309.27% | -120.44% |